ImmunityBio (IBRX) Equity Average (2015 - 2026)
ImmunityBio (IBRX) reported Equity Average of -$684.8 million for Q1 2026, down 26.98% year-over-year from -$937.8 million in Q1 2025, and down 33.77% on a QoQ basis from -$511.9 million in Q4 2025.
ImmunityBio (IBRX) has 12 years of Equity Average data on file, last reported at -$684.8 million in Q1 2026.
- Quarterly Equity Average fell 26.98% year-over-year to -$684.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$684.8 million (down 26.98% YoY) and the FY2025 annual result came in at -$494.3 million, up 7.96% from the prior year.
- Equity Average fell to -$684.8 million in Q1 2026 per IBRX's latest filing, from -$511.9 million in the prior quarter.
- Across five years, Equity Average topped out at -$290.7 million in Q1 2022 and bottomed at -$720.8 million in Q3 2024.
- The 5-year median for Equity Average is -$539.3 million (2025), against an average of -$539.6 million.
- The widest annual swing landed in 2022, when Equity Average sank 144.18%; it then rose 24.16% in 2025.
- Tracing IBRX's Equity Average over 5 years: stood at -$439.5 million in 2022, then fell by 13.39% to -$498.3 million in 2023, then retreated by 23.65% to -$616.1 million in 2024, then gained by 16.91% to -$511.9 million in 2025, then tumbled by 33.77% to -$684.8 million in 2026.
- Per Business Quant, the three latest IBRX Equity Average figures stand at -$684.8 million (Q1 2026), -$511.9 million (Q4 2025), and -$546.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 932.28 Mn |
| 10 | ImmunityBio | 7.72 Bn | 7.34 Bn | 43.97 Mn | -684.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -684.80 Mn |
| Dec 31, 2025 | -511.94 Mn |
| Sep 30, 2025 | -546.61 Mn |
| Jun 30, 2025 | -580.15 Mn |
| Mar 31, 2025 | -539.31 Mn |
| Dec 31, 2024 | -616.15 Mn |
| Sep 30, 2024 | -720.77 Mn |
| Jun 30, 2024 | -694.18 Mn |
| Mar 31, 2024 | -638.46 Mn |
| Dec 31, 2023 | -498.29 Mn |
| Sep 30, 2023 | -527.91 Mn |
| Jun 30, 2023 | -588.45 Mn |
| Mar 31, 2023 | -490.77 Mn |
| Dec 31, 2022 | -439.45 Mn |
| Sep 30, 2022 | -425.53 Mn |
| Jun 30, 2022 | -379.77 Mn |
| Mar 31, 2022 | -290.73 Mn |
| Dec 31, 2021 | -216.93 Mn |
| Sep 30, 2021 | -174.26 Mn |
| Jun 30, 2021 | -171.96 Mn |
| Mar 31, 2021 | -151.91 Mn |
| Dec 31, 2020 | -84.78 Mn |
| Sep 30, 2020 | -18.35 Mn |
| Jun 30, 2020 | -3.16 Mn |
| Mar 31, 2020 | -2.19 Mn |
| Dec 31, 2019 | 76.14 Mn |
| Sep 30, 2019 | 143.61 Mn |
| Jun 30, 2019 | 159.54 Mn |
| Mar 31, 2019 | 124.88 Mn |
| Dec 31, 2018 | 122.01 Mn |
| Sep 30, 2018 | 171.86 Mn |
| Jun 30, 2018 | 191.00 Mn |
| Mar 31, 2018 | 209.60 Mn |
| Dec 31, 2017 | 228.27 Mn |
| Sep 30, 2017 | 245.31 Mn |
| Jun 30, 2017 | 265.65 Mn |
| Mar 31, 2017 | 285.89 Mn |
| Dec 31, 2016 | 302.15 Mn |
| Sep 30, 2016 | 319.12 Mn |
| Jun 30, 2016 | 335.93 Mn |
| Mar 31, 2016 | 350.25 Mn |
| Dec 31, 2015 | 359.07 Mn |
| Sep 30, 2015 | 244.33 Mn |